Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018

Erin F. Gillespie a,b,1, Kaitlyn Lapen a,1, Diana G. Wang a, N. Wijetunga a, Gerri L. Pastrana a, Marisa A. Kollmeier a, Josh Yamada a, Adam M. Schmitt a, Daniel S. Higginson a, Max Vaynrub c, Ernesto Santos Martin d, Amy J. Xu a, C. Tsai a, Divya Yerramilli a, Oren Cahlon a, T. Yang a

a Department of Radiation Oncology, Precision Radiation for Oligometastatic and Metastatic Disease (PROMISE) Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
b Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, USA
c Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
d Department of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ABSTRACT

Article history:
Received 10 September 2020
Accepted 2 October 2020
Available online 8 October 2020

Keywords:
Bone metastases
Radiation therapy
Stereotactic body radiation therapy
End-of-life
Palliative care

Background: Bone metastases cause significant morbidity in patients with cancer, and radiation therapy (RT) is an effective treatment approach. Indications for more complex ablative techniques are emerging. We sought to evaluate RT trends at a large multi-site tertiary cancer center.

Methods: Patients who received RT for bone metastases at a single institution (including regional outpatient clinics) from 2016 to 2018 were identified. Patients were grouped by RT regimen: single-fraction conventional RT (8 Gy/C21), 30 Gy in 10 fractions, SBRT, and “other”. Multinomial logistic regression was performed to assess trends in regimens over time. Binary logistic regression was performed to evaluate factors associated with receipt of SBRT.

Results: Between 2016 and 2018, 5,952 RT episodes were received by 2,969 patients with bone metastases. Overall, 76% of episodes were 5 fractions. The median number of fractions planned for SBRT and non-SBRT episodes was 3 (IQR 3–3) and 5 (IQR 5–10), respectively. Use of SBRT increased from 2016 to 2018 (39% to 53%, p < 0.01) while use of 30 Gy in 10 fractions decreased (26% to 12%, p < 0.01), and 8 Gy/C21 was stable (5.3% to 6.9%, p = 0.28). SBRT was associated with higher performance status (p < 0.01) and non-radiosensitive histology (p < 0.01). Use of SBRT increased in the regional network (19% to 48%, p < 0.01) and at the main center (52% to 59%, p = 0.02), but did not increase within 30 days of death. More patients treated with 8 Gy/C21 than SBRT died within 30 days of treatment (24% vs 3.8%, respectively, p < 0.01).

Conclusions: SBRT is replacing 30 Gy in 10 fractions for bone metastases, especially among patients with high performance status and non-radiosensitive histologies. Better prognostic algorithms could further improve patient-centered treatment selection at the end of life.

© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Bone metastases are common among patients with metastatic cancer, with a cumulative incidence reported as high as 60–70% for breast and prostate cancer [1,2]. Bone metastases cause debilitating pain and contribute significantly to morbidity, while radiation therapy (RT) can provide effective palliation [3].

American Society for Radiation Oncology (ASTRO) guidelines recommend the use of single-fraction RT for bone metastases, especially for patients with limited life expectancy [4], and discourage any use of extended-fraction RT (>10 fractions). Nonetheless, single-fraction RT is infrequent (4–9%) and extended-fractionation persists across the United States [5–7]. Meanwhile, evidence is emerging from randomized trials suggesting SBRT may improve pain response in the palliative setting [8], and overall survival for oligometastatic disease [9–11], with

https://doi.org/10.1016/j.ctro.2020.10.001
2405-6308/C 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publications as early as 2016. However, ASTRO guidelines (2017 update) still specify using SBRT for bone metastases only within the setting of a clinical trial [12].

Based on institutional data published as early as 2008 [13], our institution has been early adopters of SBRT for bone metastases, with dedicated experts in radiation oncology establishing both Spine (2009) and Metastatic Disease Teams (2016) to formalize internal guidelines integrating experience and best available evidence. Additionally, in 2014, an institutional initiative launched to reduce practice variation across all clinical practice sites.

Using longitudinal data from a large multi-site comprehensive cancer center, we evaluated trends in RT modality and fractionation for bone metastases from 2016 to 2018, with an emphasis on SBRT, 30 Gy in 10 fractions, and 8 Gy in one fraction (8 Gy × 1). We analyzed patient and tumor characteristics associated with treatment selection, including appropriate use at end of life. Importantly, we evaluated changes in practice in our community-based regional outpatient clinics compared to the main hospital-based center.

2. Methods

We identified all patients who received RT for bone metastases at a single institution between January 1, 2016–December 31, 2018. Cases were identified through a radiation oncology treatment database query using the International Classification of Disease version 10 diagnosis code for bone metastases. Review of the electronic medical record was performed to collect each patient’s treatment setting (main hospital or regional clinic), primary tumor histology, Karnofsky Performance Scale (KPS) score, and survival following the start of treatment. The KPS score was obtained from the patient’s initial consultation, and therefore subsequent RT episodes were removed from this multivariable analysis.

Treatment episodes were categorized into the following groups: 1) SBRT (defined as treatments in which the dose was > 6 Gy per fraction in ≤ 5 fractions, except for courses where 8 Gy was delivered in one fraction), 2) all 8 Gy × 1 fraction treatments, (typically conventional technique) 3) 30 Gy in 10 fractions, and 4) all other RT regimens. Primary tumor histology was categorized as either radiosensitive or non-radiosensitive, as previously described [14]. Location of the bone metastasis was categorized as either spine or non-spine, with sacral metastases included in spine, as previously described [15,16].

Descriptive statistics were used to summarize patient characteristics. For continuous variables, we report medians and the interquartile range (IQR). We used a Kruskal-Wallis test to compare continuous variables between the RT regimen groups. A chi-squared test was used to assess rate of death within 30 days of RT by treatment regimen. To determine whether the proportion of RT regimens used over time changed, we calculated the proportion of non-spine bone metastases 44% in 2016 and 46% in 2018 (p = 0.32). Common RT regimens included SBRT (n = 2,790, 47%) and 30 Gy in 10 (n = 1,113, 19%), while 8 Gy × 1 was infrequent (n = 368, 6.2%). About one-third (n = 1,681, 28%) of RT episodes were classified as “other”, of which most (70%, n = 1,183) were 5-fraction regimens (20 Gy in 5 fractions, n = 949, and 25 Gy in 5 fractions).

Treatment episodes were categorized into the following groups: 1) SBRT (defined as treatments in which the dose was > 6 Gy per fraction in ≤ 5 fractions, except for courses where 8 Gy was delivered in one fraction), 2) all 8 Gy × 1 fraction treatments, (typically conventional technique) 3) 30 Gy in 10 fractions, and 4) all other RT regimens. Primary tumor histology was categorized as either radiosensitive or non-radiosensitive, as previously described [14]. Location of the bone metastasis was categorized as either spine or non-spine, with sacral metastases included in spine, as previously described [15,16].

Descriptive statistics were used to summarize patient characteristics. For continuous variables, we report medians and the interquartile range (IQR). We used a Kruskal-Wallis test to compare continuous variables between the RT regimen groups. A chi-squared test was used to assess rate of death within 30 days of RT by treatment regimen. To determine whether the proportion of RT regimens used over time changed, we calculated the proportion of non-spine bone metastases 44% in 2016 and 46% in 2018 (p = 0.32). Common RT regimens included SBRT (n = 2,790, 47%) and 30 Gy in 10 (n = 1,113, 19%), while 8 Gy × 1 was infrequent (n = 368, 6.2%). About one-third (n = 1,681, 28%) of RT episodes were classified as “other”, of which most (70%, n = 1,183) were 5-fraction regimens (20 Gy in 5 fractions, n = 949, and 25 Gy in 5 fractions).

Of proportions was used to assess differences in the proportions of SBRT use by treatment setting as well as rate of death within 30 days of RT by treatment regimen. Statistical calculations were conducted in R (The R Foundation, Vienna, Austria) using a p value < 0.05 for statistical significance. Institutional Review Board approval was obtained for this study.

3. Results

We identified 5,952 RT episodes for bone metastases among 2,969 unique patients. Overall, 53% (n = 1,571) of patients received one treatment episode, 23% (n = 689) received two treatment episodes, and 24% (n = 710) received three or more treatment episodes. Median patient age was 64 years (IQR 55–72 years) (see Table 1 for patient characteristics based on first treatment episode and for all treatments). Fifty-six percent (n = 3,345) of overall treatment episodes were for bone metastases located in the spine while 44% (n = 2,507) were for non-spine bone metastases. Among non-spine bone metastasis treatment episodes, the most common sites were the hip/pelvis (n = 1,050, 40%), ribs (n = 344, 13%), shoulder (n = 293, 11%), and femur (n = 298, 11%). The relative proportion of non-spine bone metastases was 44% in 2016 and 46% in 2018 (p = 0.32). Common RT regimens included SBRT (n = 2,790, 47%) and 30 Gy in 10 (n = 1,113, 19%), while 8 Gy × 1 was infrequent (n = 368, 6.2%). About one-third (n = 1,681, 28%) of RT episodes were classified as “other”, of which most (70%, n = 1,183) were 5-fraction regimens (20 Gy in 5 fractions, n = 949, and 25 Gy in 5 fractions).

Table 1

| Characteristic | Patient (n = 2,969) | Episode (n = 5,952) |
|---------------|-------------------|-------------------|
| Age (years) median (IQR) | 64 (55–72) | 63 (54–71) |
| Radiation type | | |
| SBRT n (%) | 1,384 (46.6%) | 2,790 (46.9%) |
| Other (i.e. 20 Gy in 5) n (%) | 769 (25.9%) | 1,681 (28.2%) |
| 30 Gy in 10 n (%) | 696 (23.4%) | 1,113 (18.7%) |
| 8 Gy × 1 n (%) | 120 (4.0%) | 368 (6.2%) |
| Total number of fractions median (IQR) | 5 (3–5) | 5 (3–5) |
| Primary tumor histology Radioactive | | |
| Breast n (%) | 492 (16.6%) | 830 (13.9%) |
| Prostate n (%) | 459 (15.5%) | 1,002 (16.8%) |
| Myeloma/Lymphoma n (%) | 90 (3.0%) | 187 (3.1%) |
| NSCLC n (%) | 39 (1.3%) | 71 (1.2%) |
| Other n (%) | 558 (18.8%) | 1,030 (17.3%) |
| Site of metastasis | | |
| Spine n (%) | 1,708 (57.5%) | 3,345 (56.2%) |
| Non-spine n (%) | 1,261 (42.5%) | 2,607 (43.8%) |
| RPS median (IQR) | 80 (70–90) | — |
| Treatment setting | | |
| Main hospital n (%) | 1,811 (61.0%) | 3,888 (65.3%) |
| Regional clinic n (%) | 1,158 (39.0%) | 2,074 (34.7%) |

Abbreviations: IQR = interquartile range; SBRT = stereotactic body radiation therapy; SCLC = small-cell lung cancer; NSCLC = non-small-cell lung cancer; CRC = colorectal cancer; KPS = Karnofsky Performance Scale.
fractions, n = 234). The majority (76%) of all treatments were ≤ 5 fractions, and > 10 fractions was infrequent (2.7% in 2016, 1.1% in 2018). The median number of fractions planned for SBRT and non-SBRT episodes was 3 (IQR 3–3) and 5 (IQR 5–10), respectively. The most common dose and fractionation regimen for SBRT was 27 Gy in 3 fractions (n = 1,460, 52%). A small proportion (n = 272, 4.6%) of episodes were not completed.

A multinomial logistic regression model showed a significant change in the RT regimens prescribed over time (p < 0.01). Use of SBRT increased from 2016 to 2018 (39% to 53%, p < 0.01) while 30 Gy in 10 fractions decreased (26% to 12%, p < 0.01) (Fig. 1). There was no change in the proportion of episodes using 8 Gy × 1 (p = 0.28) or “other” regimens (p = 0.45). From 2016 to 2018, the increase in the proportion of patients treated with SBRT was most prominent in patients treated at the community-based regional outpatient clinics (19% to 48%, p < 0.01) though the main hospital setting also showed a significant increase (52% to 59%, p = 0.02) (Fig. 2). Meanwhile, the proportion of patients who received 30 Gy × 10 decreased from 47% to 21% (p < 0.01) and 20% to 12% (p < 0.01) in the regional clinics and main hospital, respectively.

Patients who received 8 Gy × 1 fraction were more likely to be older (median = 70 [60–78] years vs. 64 [55–72] years, p < 0.01) and have a lower KPS (median = 70 [60–80] vs. 80 [70–90], p < 0.01) compared to all other regimens. On multivariable logistic regression, factors associated with receipt of SBRT were high KPS, a non-radiosensitive primary tumor histology, location in spine, and treatment at the main hospital. The odds of receiving SBRT increased over time in greater magnitude in the regional setting compared to the main campus; at the main campus the odds increased in 2017 compared to 2016 (OR: 1.64, 95% CI 1.14–2.36) and increased in 2018 compared to 2016 (OR: 2.42, 95% CI 1.63–3.57) (Table 2).

Overall, the rate of any radiation for bone metastases within 30 days of death was 8.4%; 10% in 2016 and 8.1% in 2018 (p = 0.09) (Fig. 3). Death within 30 days occurred among 24% of all 8 Gy × 1 treatments and 3.8% of all SBRT treatments (p < 0.01). There was no significant change in the rate of RT use within 30 days of death by RT regimen.

4. Discussion

This investigation presents recent trends in radiation dose and fractionation for bone metastases at a large multi-site tertiary cancer center in the United States. We found that 30 Gy in 10 fractions of conventional radiation has largely been replaced by SBRT, which is most often delivered in 3 fractions. A prior analysis of Medicare claims from 2010 to 2014 observed an increase in the use of SBRT for bone metastases, though overall use was still low [17]. In our study, nearly half of patients are receiving SBRT for bone metastases.

With randomized evidence addressing the use of SBRT for bone metastases still emerging, ASTRO guidelines (last updated 2017) recommend using SBRT in the setting of a clinical trial [4]. Nonetheless, during the study period (2016–2018) for patients with high performance status and radiosensitive histology, SBRT appears to be the preferred option among metastatic specialists at our institution. Use of SBRT for bone metastases in the spine is based on institutional experience suggesting improved long-term tumor control with high-dose RT [13,18], which prompted early development of institutional guidelines in 2009 [19,20], and was later supported by prospective, albeit single-arm, data from other institutions [20]. More recently, randomized evidence suggests SBRT may provide more rapid as well as more durable pain control in patients with non-spine bone metastases surviving at least

Fig. 1. Radiation treatment regimens for bone metastases from 2016 to 2018.
SBRT treatments over time, there was no concomitant increase in the proportion of patients dying within 30 days of SBRT. Prognostic models could further improve appropriate selection of RT regimen at the end of life, reducing cost as well as time spent in simulation and treatment in a patient’s final days. Current models designed for patients with metastatic disease include TEACHH [26] and the NEAT [27], though accuracy of prognostic predictions may be limited by rapidly evolving systemic treatments. Additionally, evaluation of biomarkers that predict tumor and symptom response to SBRT is warranted and currently underway to optimize treatment selection.

It is noteworthy that the increase in utilization of SBRT from 2016 to 2018 was most evident in our community-based regional outpatient clinics, which now have similar rates of SBRT as our main campus. Reduction in variation is generally desirable [28] and was achieved in part through an institutional initiative (started in 2014) to improve consistency in practice across our Regional Care Network. Specific strategies included 1) establishment of dedicated specialized radiation oncologists for treatment of metastatic disease at each clinical site, 2) development, dissemination, and semi-annual retreats to review practice guidelines in both Spine and Metastatic disease teams within radiation oncology, 3) access to multidisciplinary tumor boards with contour review for difficult cases, 4) standardized cross-campus workflows for simulation and treatment setup, 5) centralized peer review for all metastatic radiation plans, and 6) ongoing monitoring of practice patterns with feedback.

There are several limitations to this investigation, including the lack of detailed clinical characteristics available, such as extent of metastatic disease (i.e. presence of oligometastasis), visceral organ involvement, and presence of soft tissue extension, which may further determine RT regimen selection. Additionally, for patients that had more than one recorded RT episode within our study period, certain clinical variables were only available for the first episode due to limitations of the database query. Nonetheless, this report provides a snapshot of the recent preference for avoiding radiation that extends longer than 5 fractions, and reinforcing considerations of factors such as KPS and histology in the consideration for SBRT use in both spine and non-spine bone metastases.

### Table 2: Factors associated with use of SBRT (vs. other modalities).

| Factor                          | Univariable analysis | Multivariable analysis |
|---------------------------------|----------------------|------------------------|
|                                 | OR (95% CI)          | OR (95% CI)            |
|                                 | p value              | p value                |
| Age                             |                      |                        |
| ≤ 64 years                      | -                    | -                      |
| > 64 years                      | 1.14 (0.88–1.47)     | 0.31                   |
|                                 | 1.58 (1.18–2.12)     | <0.01                  |
| KPS                             | -                    |                        |
| ≤ 80                            | -                    | -                      |
| > 80                            | 8.99 (6.17–13.09)    | <0.01                  |
|                                 | 7.88 (5.37–11.56)    | <0.01                  |
| Primary tumor histology         |                      |                        |
| Radiosensitive                  | -                    | -                      |
| Non-radiosensitive              | 6.85 (4.91–9.55)     | <0.01                  |
|                                 | 9.36 (6.43–13.62)    | <0.01                  |
| Site of metastasis              | -                    | -                      |
| Spine                           | 3.01 (2.44–3.71)     | <0.01                  |
|                                 | 2.84 (2.27–3.55)     | <0.01                  |
| Location*                       | -                    | -                      |
| Main                            | 0.31 (0.20–0.49)     | <0.01                  |
|                                 | 0.37 (0.24–0.59)     | 0.01                   |
| Regional Year*                  | -                    | -                      |
| 2016                            | -                    | -                      |
| 2017                            | 8.10 (4.77–13.75)    | <0.01                  |
|                                 | 8.68 (4.95–15.21)    | <0.01                  |
| 2018                            | 14.92 (8.85–25.75)   | <0.01                  |
|                                 | 12.98 (7.29–23.13)   | <0.01                  |

Abbreviations: SBRT = stereotactic body radiation therapy; OR = odds ratio; CI = confidence interval.

*Estimates shown are for 2018 only. A similar relationship was seen in 2016 and 2017.

*Estimates shown are for regional site only.
5. Conclusions

For patients with high performance status, longer life expectancy, and non-radiosensitive tumors that might have historically received 10 fractions, SBRT is increasingly favored over conventional radiation. Rapid uptake is feasible in the community-based outpatient clinic setting when leadership prioritizes network integration, and clinical practice guidelines are supported by difficult case conferences and peer review. Use of algorithms that accurately predict life expectancy is warranted to increase use of 8 Gy x 1 for bone metastases within a patient’s last 30 days, further optimizing patient-centered care and treatment-related costs.

6. Conflicts of Interest/Disclosures

EFG is a cofounder of the educational website eContour.org. KL is in a research fellowship funded by grants for research and education related to eContour.org. CJT is a consultant with Varian Medical Systems, Inc. All other authors have no disclosures.

Credit authorship contribution statement

Erin F. Gillespie: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. Kaitlyn Lapen: Conceptualization, Data curation, Formal analysis, Project administration, Software, Validation, Visualization, Writing - original draft, Writing - review & editing. Diana G. Wang: Conceptualization, Data curation, Formal analysis, Validation, Writing - original draft, Writing - review & editing. N. Wijetunga: Conceptualization, Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing - original draft, Writing - review & editing. Gerri L. Pastrana: Conceptualization, Data curation, Project administration, Writing - original draft, Writing - review & editing. Marisa A. Kollmeier: Conceptualization, Data curation, Formal analysis, Writing - original draft, Writing - review & editing. Josh Yamada: Conceptualization, Supervision, Writing - original draft, Writing - review & editing. Adam M. Schmitt: Conceptualization, Supervision, Writing - original draft, Writing - review & editing. Ernesto Santos Martin: Conceptualization, Supervision, Writing - original draft, Writing - review & editing. Amy J. Xu: Conceptualization, Writing - original draft, Writing - review & editing. C. Tsai: Conceptualization, Formal analysis, Methodology, Writing - original draft, Writing - review & editing. Divya Yerramilli: Conceptualization, Supervision, Writing - original draft, Writing - review & editing. Oren Cahlon: Conceptualization, Supervision, Writing - original draft, Writing - review & editing. T. Yang: Conceptualization, Methodology, Resources, Supervision, Writing - original draft, Writing - review & editing.

Acknowledgements

This article was supported by funds from the Memorial Sloan Kettering Cancer Center Grant (P30 CA008748). It was also supported by a National Comprehensive Cancer Network (NCCN) Pfizer EMBRACE (Ending Metastatic Breast Cancer for Everyone) program grant. The funders/sponsors had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. We acknowledge the leadership of Dr. Simon Powell and Dr. Oren Cahlon for supporting the development of the Metastatic Disease Team and integration of Memorial Sloan Kettering’s Regional Network.

References

[1] Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH. Incidence of bone metastases: an overview. Oncol Rev 2019;5(6):872–8.
[2] Macedo F, Ladeira K, Pinho F, et al. Bone metastases: an overview. Oncol Rev 2019;5(6):872–8.
[3] Palma DA, Olson R, Harrow S, et al. Palliative radiation therapy fractionation for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 2015;91(3):548–55.
[4] Gupta A, Wang P, Sedhom R, et al. Physician practice variability in the use of extended-fraction radiation therapy for bone metastases: are we choosing wisely? JCO Oncol Pract 2020:JOP1900633.
[5] Nguyen QN, Chun SC, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol 2019;5(6):872–8.
[6] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393 (10185):2051–8.
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020.

Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019;37(18):1558–65.

Pan H, Simpson DR, Meuller AJ, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011;117(19):4566–72.

Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019;37(18):1558–65.

Pan H, Simpson DR, Meuller AJ, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011;117(19):4566–72.

Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008;71(2):484–90.

Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013;18(6):744–51.

Chow E, van der Linden YM, Roos D, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15(2):164–71.

Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2013;7(4):965–79.

Logan JK, Jiang J, Shih YT, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2013;7(4):965–79.

Yamada Y, Katsoulakis E, Laufer I, et al. The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery. Neurosurg Focus 2017;42(1):E6.

Chow E, van der Linden YM, Roos D, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15(2):164–71.

Laufer I, Rubin DG, Lis E, et al. The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 2013;18(6):744–51.

Chow E, van der Linden YM, Roos D, et al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 2014;15(2):164–71.

Yamada Y, Katsoulakis E, Laufer I, et al. The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery. Neurosurg Focus 2017;42(1):E6.

Gerszten PC, Mendel E, Yamada Y, Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34(22 Suppl):S78–92.

Gerszten PC, Mendel E, Yamada Y, Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009;34(22 Suppl):S78–92.